A laboratory technician dissolves an active ingredient for the antiviral drug remdesivir in a tank at the Eva Pharma facility in Cairo on Aug. 30. (Sima Diab/Bloomberg News)

The commercial success of remdesivir, despite its narrow benefit for hospitalized coronavirus patients, highlights the lack of potent tools for doctors six months into the pandemic.